BACKGROUND: Serine racemase (SRR) is a brain-enriched enzyme that converts L-serine to D-serine, which acts as an endogenous ligand of N-methyl D-aspartate (NMDA) receptors. Dysfunction of SRR may reduce the function of NMDA receptors and susceptibility to schizophrenia. METHODS: We genotyped three single-nucleotide polymorphisms (SNPs) of the 5' region of the SRR gene in 525 patients with schizophrenia and 524 healthy controls. Effects of SNPs on the promoter activity and on serum levels of total and D-serine were examined. RESULTS: We found a significant excess of the IVS1a+465C allele of the SRR gene in schizophrenia, especially in the paranoid subtype (p = .0028). A reporter assay showed that the IVS1a+465C allele had 60% lower promoter activity than did the IVS1a+465G allele. CONCLUSIONS: The IVS1a+465C allele of the SRR gene, which reduces expression of the gene, is a risk factor for schizophrenia, especially the paranoid subtype.
BACKGROUND:Serine racemase (SRR) is a brain-enriched enzyme that converts L-serine to D-serine, which acts as an endogenous ligand of N-methyl D-aspartate (NMDA) receptors. Dysfunction of SRR may reduce the function of NMDA receptors and susceptibility to schizophrenia. METHODS: We genotyped three single-nucleotide polymorphisms (SNPs) of the 5' region of the SRR gene in 525 patients with schizophrenia and 524 healthy controls. Effects of SNPs on the promoter activity and on serum levels of total and D-serine were examined. RESULTS: We found a significant excess of the IVS1a+465C allele of the SRR gene in schizophrenia, especially in the paranoid subtype (p = .0028). A reporter assay showed that the IVS1a+465C allele had 60% lower promoter activity than did the IVS1a+465G allele. CONCLUSIONS: The IVS1a+465C allele of the SRR gene, which reduces expression of the gene, is a risk factor for schizophrenia, especially the paranoid subtype.
Authors: Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine Journal: Pharmacol Rev Date: 2010-09 Impact factor: 25.468
Authors: Elin Grundberg; Tony Kwan; Bing Ge; Kevin C L Lam; Vonda Koka; Andreas Kindmark; Hans Mallmin; Joana Dias; Dominique J Verlaan; Manon Ouimet; Daniel Sinnett; Fernando Rivadeneira; Karol Estrada; Albert Hofman; Joyce M van Meurs; André Uitterlinden; Patrick Beaulieu; Alexandru Graziani; Eef Harmsen; Osten Ljunggren; Claes Ohlsson; Dan Mellström; Magnus K Karlsson; Olle Nilsson; Tomi Pastinen Journal: Genome Res Date: 2009-08-04 Impact factor: 9.043
Authors: John E Lisman; Joseph T Coyle; Robert W Green; Daniel C Javitt; Francine M Benes; Stephan Heckers; Anthony A Grace Journal: Trends Neurosci Date: 2008-04-07 Impact factor: 13.837
Authors: Viviane Labrie; Ryutaro Fukumura; Anjali Rastogi; Laura J Fick; Wei Wang; Paul C Boutros; James L Kennedy; Mawahib O Semeralul; Frankie H Lee; Glen B Baker; Denise D Belsham; Steven W Barger; Yoichi Gondo; Albert H C Wong; John C Roder Journal: Hum Mol Genet Date: 2009-05-30 Impact factor: 6.150
Authors: L M DeVito; D T Balu; B R Kanter; C Lykken; A C Basu; J T Coyle; H Eichenbaum Journal: Genes Brain Behav Date: 2010-11-02 Impact factor: 3.449
Authors: A C Basu; G E Tsai; C-L Ma; J T Ehmsen; A K Mustafa; L Han; Z I Jiang; M A Benneyworth; M P Froimowitz; N Lange; S H Snyder; R Bergeron; J T Coyle Journal: Mol Psychiatry Date: 2008-12-09 Impact factor: 15.992